Citations

Clear

6274 citation(s) found for "To, Andrew".

Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma
Prabhu, Sujit S. , Rao, Ganesh , Laxton, Adrian W. , Fecci, Peter E. , O’Brien, Barbara , Sloan, Andrew E. , Chiang, Veronica , Mohammadi, Alireza M. , Chen, Clark, Sun, David, Sinicrope, Kaylyn, Campian, Jian , Kurz, Sylvia C. , Smith, Kris A. , Tovar-Spinoza, Zulma , Leuthardt, Eric C. , Khasraw, Mustafa , Fecci, Peter E , Groot, John de , Kim, Albert H. , Tatter, Stephen B. , Placantonakis, Dimitris G. , Strowd, Roy E. , Hadjipanayis, Costas G. , Khasraw, Mustafa , Piccioni, David Eric , Williams, Brian J.

Mayo Clinic

Neuro-Oncology Advances | April 6, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac040 | PMID 35611270 Get It

Abstract Background Treatment options for unresectable new and recurrent glioblastoma remain limited. Laser ablation has demonstrated safety as a surgical approach to treating primary brain tumors. The LAANTERN prospective multicenter registry (NCT02392078) data were analyzed to determine clinical outcomes for patients with new and recurrent IDH wild-type glioblastoma. Methods Demographics, intraprocedural data, adverse events, KPS, health economics, and survival data were prospectively collected and then analyzed on IDH wild-type newly diagnosed and recurrent glioblastoma patients who were treated with laser ablation at 14 US centers between January 2016 and May 2019. Data were monitored for accuracy. Statistical analysis included individual variable summaries, multivariable differences in survival, and median survival numbers. Results A total of 29 new and 60 recurrent IDH wild-type WHO grade 4 glioblastoma patients were treated. Positive MGMT promoter methylation status was present in 5/29 of new and 23/60 of recurrent patients. Median physician-estimated extent of ablation was 91%-99%. Median overall survival (OS) was 9.73 months (95% confidence interval: 5.16, 15.91) for newly diagnosed patients and median post-procedure survival was 8.97 months (6.94, 12.36) for recurrent patients. Median OS for newly diagnosed patients receiving post-LITT chemo/radiation was 16.14 months (6.11, not reached). Factors associated with improved survival were MGMT promoter methylation, adjuvant chemotherapy within 12 weeks, and tumor volume <3 cc. Conclusions Laser ablation is a viable option for patients with new and recurrent glioblastoma. Median OS for IDH wild-type newly diagnosed glioblastoma is comparable to outcomes observed in other tumor resection studies when those patients undergo radiation and chemotherapy following LITT.
Diabetes mellitus in relation to colorectal tumor molecular subtypes: A pooled analysis of more than 9000 cases
Harlid, Sophia , Guelpen, Bethany Van , Gylling, Björn , Aglago, Elom K. , Amitay, Efrat L. , Brenner, Hermann , Buchanan, Daniel D. , Cao, Yin , Chang‐Claude, Jenny , Drew, David A. , Figueiredo, Jane C. , French, Amy J. , Gallinger, Steven , Giannakis, Marios , Hoffmeister, Michael , Newton, Christina C. , Obón‐Santacana, Mireia , Song, Mingyang , Steinfelder, Robert S. , Thibodeau, Stephen N. , Woods, Michael O. , Phipps, Amanda I. , Harrison, Tabitha A. , Peters, Ulrike , Van Guelpen, Bethany , Amitay, Efrat L , Buchanan, Daniel D , Hoffmeister, Michael , Moreno, Victor , Murphy, Neil , Song, Mingyang , Cao, Yin , Drew, David A , Harrison, Tabitha A , Brenner, Hermann , Aglago, Elom K , Obón-Santacana, Mireia , Qu, Conghui , Campbell, Peter T. , Chan, Andrew T. , Giles, Graham G. , Gunter, Marc J. , Jenkins, Mark A. , Lin, Yi , Moreno, Vı́ctor , Murphy, Neil , Newcomb, Polly A. , Nowak, Jonathan A. , Ogino, Shuji , Potter, John D. , Sun, Wei , Toland, Amanda Ewart , Ugai, Tomotaka , Um, Caroline Y.

Mayo Clinic

International Journal of Cancer | April 6, 2022 | Volume: 151 | Issue: 3 | Pages: 348-360

10.1002/ijc.34015 | PMID 35383926 Get It

AbstractDiabetes is an established risk factor for colorectal cancer. However, colorectal cancer is a heterogeneous disease and it is not well understood whether diabetes is more strongly associated with some tumor molecular subtypes than others. A better understanding of the association between diabetes and colorectal cancer according to molecular subtypes could provide important insights into the biology of this association. We used data on lifestyle and clinical characteristics from the Colorectal Cancer Family Registry (CCFR) and the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), including 9756 colorectal cancer cases (with tumor marker data) and 9985 controls, to evaluate associations between reported diabetes and risk of colorectal cancer according to molecular subtypes. Tumor markers included BRAF and KRAS mutations, microsatellite instability and CpG island methylator phenotype. In the multinomial logistic regression model, comparing colorectal cancer cases to cancer‐free controls, diabetes was positively associated with colorectal cancer regardless of subtype. The highest OR estimate was found for BRAF‐mutated colorectal cancer, n = 1086 (ORfully adj: 1.67, 95% confidence intervals [CI]: 1.36‐2.05), with an attenuated association observed between diabetes and colorectal cancer without BRAF‐mutations, n = 7959 (ORfully adj: 1.33, 95% CI: 1.19‐1.48). In the case only analysis, BRAF‐mutation was differentially associated with diabetes (Pdifference = .03). For the other markers, associations with diabetes were similar across tumor subtypes. In conclusion, our study confirms the established association between diabetes and colorectal cancer risk, and suggests that it particularly increases the risk of BRAF‐mutated tumors.
Implementation of Clinical Practice Guidelines for Hospitalized Patients With COVID-19 in Academic Medical Centers
Berger, Amy, Simchoni, Noa , Auerbach, Andrew D., Brode, W. Michael , Kuperman, Ethan , Kubey, Alan , Group, HOMERuN COVID-19 Collaborative, Auerbach, Andrew D. , Raffel, Katie E. , Kubey, Alan A , Group, HOMERuN COVID-19 Collaborative

Mayo Clinic

JAMA Network Open | April 4, 2022 | Volume: 5 | Issue: 4 | Pages: e225657

10.1001/jamanetworkopen.2022.5657 | PMID 35377428 Get It

The Intensivist's Perspective of Shock, Volume Management, and Hemodynamic Monitoring
Kashani, Kianoush , Omer, Tarig, Shaw, Andrew D., Kashani, Kianoush B , Omer, Tarig, Shaw, Andrew D.

Mayo Clinic

Clinical Journal of the American Society of Nephrology | April 4, 2022 | Volume: 17 | Issue: 5 | Pages: 706-716

10.2215/cjn.14191021 | PMID 35379765 Get It

One of the primary reasons for intensive care admission is shock. Identifying the underlying cause of shock (hypovolemic, distributive, cardiogenic, and obstructive) may lead to entirely different clinical pathways for management. Among patients with hypovolemic and distributive shock, fluid therapy is one of the leading management strategies. Although an appropriate amount of fluid administration might save a patient's life, inadequate (or excessive) fluid use could lead to more complications, including organ failure and mortality due to either hypovolemia or volume overload. Currently, intensivists have access to a wide variety of information sources and tools to monitor the underlying hemodynamic status, including medical history, physical examination, and specific hemodynamic monitoring devices. Although appropriate and timely assessment and interpretation of this information can promote adequate fluid resuscitation, misinterpretation of these data can also lead to additional mortality and morbidity. This article provides a narrative review of the most commonly used hemodynamic monitoring approaches to assessing fluid responsiveness and fluid tolerance. In addition, we describe the benefits and disadvantages of these tools.
European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing
Wilde, Arthur A.M. , Semsarian, Christopher, Shamloo, Alireza Sepehri , Ackerman, Michael J. , Ashley, Euan A. , Eduardo, Back Sternick, Barajas-Martínez, Héctor , Behr, Elijah R. , Breckpot, Jeroen , Chockalingam, Priya , Crotti, Lia , Lubitz, Steven A. , Makita, Naomasa , Ohno, Seiko, Ortiz‐Genga, Martín, Sacilotto, Luciana , Schulze‐Bahr, Eric , Sotoodehnia, Nona , Tadros, Rafik, Ware, James S. , Kaufman, Elizabeth S. , Aiba, Takeshi , Bollmann, Andreas, Choi, Jong‐Il , Dalal, Aarti , Darrieux, Francisco , Giudicessi, John, Guerchicoff, Mariana , Intyre, Ciorsti Mac, Mackall, Judith A. , Napolitano, Carlo , Juan, Pablo Ochoa, Peichl, Petr , Pereira, Alexandre C. , Skinner, Jon, Tfelt‐Hansen, Jacob , Deneke, Thomas, Mac Intyre, Ciorsti, Crotti, Lia , Makita, Naomasa , Behr, Elijah Raphael , Tfelt-Hansen, Jacob , Lubitz, Steven A , Peichl, Petr , Ware, James S , Márquez, Manlio F. , Bezzina, Connie R. , Charron, Philippe , Gollob, Michael H. , Ohno, Seiko , Shimizu, Wataru , Winlaw, David Scott , Aiba, Takeshi , Giudicessi, John R. , Hong, Kui , Krahn, Andrew D. , Mont, Lluís , Schwartz, Peter J. , Stellbrink, Christoph , Deneke, Thomas

Mayo Clinic

Journal of Arrhythmia | April 4, 2022 | Volume: 38 | Issue: 4 | Pages: 491-553

10.1002/joa3.12717 | PMID 35936045 Get It

European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases
Wilde, Arthur A.M. , Semsarian, Christopher, Shamloo, Alireza Sepehri , Ackerman, Michael J. , Ashley, Euan A. , Barajas-Martinez, Héctor, Behr, Elijah R. , Breckpot, Jeroen , Chockalingam, Priya, Crotti, Lia , Lubitz, Steven A. , Makita, Naomasa , Ohno, Seiko , Ortiz‐Genga, Martín, Sacilotto, Luciana, Schulze‐Bahr, Eric , Sotoodehnia, Nona , Ware, James S. , Kaufman, Elizabeth S. , Reviewers, Document, Aiba, Takeshi , Bollmann, Andreas, Choi, Jong‐Il , Dalal, Aarti , Darrieux, Francisco , Giudicessi, John, Guerchicoff, Mariana , MacIntyre, Ciorsti, Mackall, Judith A. , Napolitano, Carlo , Ochoa, Juan Pablo , Peichl, Petr , Pereira, Alexandre C., Skinner, Jon, Tfelt‐Hansen, Jacob , Deneke, Thomas, Crotti, Lia , Sacilotto, Luciana , Chockalingam, Priya , Crotti, Lia , Makita, Naomasa , Behr, Elijah Raphael , Tfelt-Hansen, Jacob , Lubitz, Steven A , Peichl, Petr , Ware, James S , Márquez, Manlio F. , Sternick, Eduardo Back , Bezzina, Connie R. , Charron, Philippe , Gollob, Michael H. , Ohno, Seiko , Shimizu, Wataru , Tadros, Rafik , Winlaw, David Scott , Reviewers, Document, Aiba, Takeshi , Giudicessi, John R. , Hong, Kui , Krahn, Andrew D. , Mont, Lluís , Schwartz, Peter J. , Stellbrink, Christoph , Deneke, Thomas

Mayo Clinic

Europace | April 4, 2022 | Volume: 24 | Issue: 8 | Pages: 1307-1367

10.1093/europace/euac030 | PMID 35373836 Get It

The utility of dual-energy computed tomography in abdominal imaging
Gaizo, Andrew J. Del , Silva, Alvin C. , Hara, Amy K.

Mayo Clinic

Applied Radiology | April 4, 2022 | Volume: No volume available | Issue: No issue available | Pages: 12-19

10.37549/ar2048 Get It

International consensus statement on allergy and rhinology: Olfaction
Patel, Zara M. , Holbrook, Eric H. , Turner, Justin H. , Adappa, Nithin D. , Albers, Mark W. , Altundağ, Aytuğ , Appenzeller, Simone , Costanzo, Richard M. , Croy, Ilona , Davis, Greg E. , Dehgani‐Mobaraki, Puya , Doty, Richard L. , Haehner, Antje , Hopkins, Claire , Hummel, Thomas , Jitaroon, Kawinyarat, Kern, Robert C. , Khanwalkar, Ashoke , Kobayashi, Masayoshi , Leopold, Donald A., Levy, Joshua M. , Marmura, Michael J. , Mclelland, Lisha, Miwa, Takaki , Moberg, Paul J., Mueller, Christian A. , Nigwekar, Sagar U. , O’Brien, Erin K. , Păunescu, Teodor G. , Philpott, Carl , Pinto, Jayant M. , Reiter, Evan R. , Schlosser, Rodney J. , Schwob, James E. , Seiden, Allen M., Smith, Timothy L. , Sowerby, Leigh J. , Tan, Bruce K. , Thamboo, Andrew , Wrobel, Bozena , Yan, Carol H. , Duffy, Valerie B , Goldstein, Bradley J , Gudis, David A , Haehner, Antje , Higgins, Thomas S , Hopkins, Claire , Huart, Caroline , Hummel, Thomas , Kern, Robert C , Khanwalkar, Ashoke R , Kobayashi, Masayoshi , Kondo, Kenji , Lane, Andrew P , Levy, Joshua M , Marmura, Michael J , O'Brien, Erin K , Paunescu, Teodor G , Pellegrino, Robert , Philpott, Carl , Roalf, David R , Rowan, Nicholas R , Schlosser, Rodney J , Schwob, James , Smith, Timothy L , Sowerby, Leigh , Yan, Carol , Holbrook, Eric H , Patel, Zara , Albers, Mark W , Adappa, Nithin D. , Gudis, David A. , Lechner, Matt , Rowan, Nicholas R. , Soler, Zachary M.

Mayo Clinic

International Forum of Allergy & Rhinology | April 3, 2022 | Volume: 12 | Issue: 4 | Pages: 327-680

10.1002/alr.22929 | PMID 35373533 Get It

Abstract Background The literature regarding clinical olfaction, olfactory loss, and olfactory dysfunction has expanded rapidly over the past two decades, with an exponential rise in the past year. There is substantial variability in the quality of this literature and a need to consolidate and critically review the evidence. It is with that aim that we have gathered experts from around the world to produce this International Consensus on Allergy and Rhinology: Olfaction (ICAR:O). Methods Using previously described methodology, specific topics were developed relating to olfaction. Each topic was assigned a literature review, evidence‐based review, or evidence‐based review with recommendations format as dictated by available evidence and scope within the ICAR:O document. Following iterative reviews of each topic, the ICAR:O document was integrated and reviewed by all authors for final consensus. Results The ICAR:O document reviews nearly 100 separate topics within the realm of olfaction, including diagnosis, epidemiology, disease burden, diagnosis, testing, etiology, treatment, and associated pathologies. Conclusion This critical review of the existing clinical olfaction literature provides much needed insight and clarity into the evaluation, diagnosis, and treatment of patients with olfactory dysfunction, while also clearly delineating gaps in our knowledge and evidence base that we should investigate further.
Travel-Associated Venous Thromboembolism
Johnson, Isla McKerrow , Shatzel, Joseph J. , Olson, Sven R. , Kohl, Tovah , Hamilton, Andrew , McKerrow Johnson, Isla, Johnson, Isla , DeLoughery, Thomas G.

Mayo Clinic

Wilderness & Environmental Medicine | March 31, 2022 | Volume: 33 | Issue: 2 | Pages: 169-178

10.1016/j.wem.2022.02.004 | PMID 35370084 Get It

Introduction Long-distance travel is assumed to be a risk factor for venous thromboembolism (VTE). However, the available data have not clearly demonstrated the strength of this relationship, nor have they shown evidence for the role of thromboprophylaxis. Methods We performed a systematic review of the literature. We also summarized available guidelines from 5 groups. Results We found 18 studies that addressed this question. Based on the data presented in the review, we conclude that there is an association between VTE and length of travel, but this association is mild to moderate in effect size with odds ratios between 1.1 and 4. A dose-response relationship between VTE and travel time was identified, with a 26% higher risk for every 2 h of air travel ( P=0.005) starting after 4 h. The quality of evidence for both travel length and thromboprophylaxis was low. However, low-risk prophylactic measures such as graduated compression stockings were shown to be effective in VTE prevention. There is heterogeneity among the different practice guidelines. The guidelines generally concur that no prophylaxis is necessary in travelers without known thrombosis risk factors and advocate for conservative treatment such as compression stockings over pharmacologic prophylaxis. Conclusions We conclude air travel is a risk factor for VTE and that there is a dose relationship starting at 4 h. For patients with risk factors, graduated compression stockings are effective prophylaxis.